ALX ONCOLOGY HOLDINGS INC. - COMMON STOCK

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

10 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Pricing of Public Offering

05 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces Proposed Public Offering

04 Oct 2023 16:10:18 By Nasdaq GlobeNewswire

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

03 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

02 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

ALX Oncology Realigns Executive Leadership Team

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

ALX Oncology Announces September Investor Conference Participation

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

10 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

26 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

11 May 2023 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

09 May 2023 07:00:02 By Nasdaq GlobeNewswire

ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

25 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer

13 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

09 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer

16 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

05 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

ALX Oncology Appoints Scott Garland to its Board of Directors

29 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

08 Nov 2022 16:01:00 By Nasdaq GlobeNewswire